## Gene Summary
HLA-DRB5, part of the human leukocyte antigen system, is a component located within the Major Histocompatibility Complex (MHC) class II region on chromosome 6. This gene produces a beta-chain that is a component of the MHC class II protein complex. The MHC class II proteins play a critical role in the immune system by presenting peptides derived from extracellular proteins to T cells. Expression of HLA-DRB5 is variable and can be highly influenced by genetic polymorphism. The protein encoded by this gene forms heterodimers with the alpha chains of other DR antigens, and the combinations influence the repertoire of antigens presented which affects the immune response.

## Gene Drugs, Diseases, Phenotypes, and Pathways
Due to its central role in immune response modulation, HLA-DRB5 has been associated with a susceptibility to several autoimmune and inflammatory conditions, such as multiple sclerosis, rheumatoid arthritis, and possibly type 1 diabetes. The gene's product is involved in antigen presentation pathways, which are crucial for initiating specific immune responses. Variations in the presentation pathway influenced by HLA-DRB5 can result in either protective or susceptibility effects regarding these diseases.

## Pharmacogenetics
HLA-DRB5 has important pharmacogenetic implications, particularly in the modulation of drug responses through immune mechanisms. For instance, variations in HLA-DRB5 are associated with differential responses to drugs in medical conditions like multiple sclerosis. While specific drug interactions with HLA-DRB5 are not as well characterized as for other HLA genes, the understanding of its role in disease context suggests potential influences on treatment outcomes in diseases where immune response is crucial. Consequently, studying HLA-DRB5 polymorphisms could enhance personalized treatment approaches in autoimmune diseases.